Allergy & Immunology
Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.
7 Sep, 2021 | 10:56h | UTCInvited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
Commentaries on Twitter
(thread – click for more)
Substudy suggests extended interval (up to 45 wks) before 2nd dose of ChAdOx1 nCoV-19 leads to increased antibody titres, offering more flexibility in vaccine schedules.
Extended interval before 3rd dose resulted in further increase in immune responses. https://t.co/J3xOwSSYMN pic.twitter.com/8GotDI4ctS
— The Lancet (@TheLancet) September 2, 2021
(thread – click for more)
New @TheLancet
The heightened immune response to longer spacing @AstraZeneca 1st -> 2nd vaccine doses and the response 3rd booster dose, with high neutralizing antibodies and T cellshttps://t.co/A2UcPVIFYP pic.twitter.com/zfYaW0T8Yf— Eric Topol (@EricTopol) September 1, 2021
Opinion | Video: Immunity is the only way through a pandemic (w/Dr. Monica Gandhi).
7 Sep, 2021 | 10:45h | UTCImmunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD
EU agency says to focus on vaccines first not booster shots.
3 Sep, 2021 | 10:34h | UTCEU agency says to focus on vaccines first not booster shots – Associated Press
See also: European officials say COVID-19 booster isn’t urgent – CIDRAP
RCT: In patients with Immune Thrombocytopenia, the addition of Mycophenolate Mofetil to a standard glucocorticoid regimen reduced refractory or relapsed disease but was associated with decreased quality of life outcomes regarding physical function and fatigue.
3 Sep, 2021 | 10:15h | UTC
Review | COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.
2 Sep, 2021 | 10:06h | UTC
Commentary on Twitter
NEW REVIEW—COVID-19 and immune-mediated inflammatory diseases
Filippo Fagni and colleagues @UniFAU review the effect of disease and treatment on #COVID19 outcomes and #vaccine responseshttps://t.co/ue8XnDF1sM #LancetRheumatology @KorayTascilar pic.twitter.com/Yrk4SmeSbE
— The Lancet Rheumatology (@TheLancetRheum) August 27, 2021
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
2 Sep, 2021 | 10:05h | UTCWaning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar – medRxiv
Related:
Studies: COVID vaccine protection waning against infection but not hospitalization.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
Commentary on Twitter (thread – click for more)
The evidence of mRNA vaccine effectiveness (VE) waning grows: large Qatar experience shows substantial 5 month attrition for symptomatic infection VE below 50% and, to a lesser extent, vs hospitalization and deathhttps://t.co/4lIG68Bxm0 pic.twitter.com/rnyo0Si3RP
— Eric Topol (@EricTopol) August 27, 2021
[Preprint] Pfizer vaccine booster dose protection: A nationwide study from Israel – “Twelve days or more after the booster dose we found an 11.4-fold decrease in the relative risk of confirmed infection, and a >10-fold decrease in the relative risk of severe illness”.
1 Sep, 2021 | 09:59h | UTCBNT162b2 vaccine booster dose protection: A nationwide study from Israel – medRxiv
Why is a third COVID-19 vaccine dose important for people who are immunocompromised?
1 Sep, 2021 | 09:57h | UTCRelated:
RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.
Study demonstrates a significantly higher humoral immunogenicity induced by the SARS-CoV-2 Moderna vaccine compared with the Pfizer- BioNTech vaccine.
31 Aug, 2021 | 09:04h | UTCComparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 – JAMA
Related:
Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.
New CDC Guidance says influenza and Covid vaccines can be given together – “COVID-19 vaccines and other vaccines may now be administered without regard to timing”
29 Aug, 2021 | 18:51h | UTCCommentary: Flu shot and a COVID jab? New 2021-2022 flu vaccine guidance points to both – McKnight’s
[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.
27 Aug, 2021 | 10:11h | UTCPress release: Is COVID vaccine protection fading? – ZOE Covid Study
Commentaries:
Covid infection protection waning in double jabbed – BBC
[Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.
27 Aug, 2021 | 10:16h | UTC
Commentary on Twitter (thread – click for more)
Interesting and a lot of threads already but I wanna throw a spanner in the works with an annoying question that I hope someone will be able to answer so I can better understand the relevance of this study.https://t.co/5cE0omt6FH
— Andrew L. Croxford (@andrew_croxford) August 26, 2021
Johnson & Johnson booster shot prompts large increase in immune response, company says.
26 Aug, 2021 | 09:14h | UTCJohnson & Johnson booster shot prompts large increase in immune response, company says – CNN
News release: Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.
26 Aug, 2021 | 08:32h | UTC
Covid-19 booster vaccines: What we know and who’s doing what.
24 Aug, 2021 | 10:04h | UTCCovid-19 booster vaccines: What we know and who’s doing what – The BMJ
Opinion | The FDA really did have to take this long – “If vaccine approval feels maddeningly scrupulous, that’s because the alternative is worse”.
24 Aug, 2021 | 10:01h | UTCThe FDA Really Did Have to Take This Long – The Atlantic
COVID vaccines protect against Delta, but their effectiveness wanes.
24 Aug, 2021 | 09:57h | UTCCOVID vaccines protect against Delta, but their effectiveness wanes – Nature
Original study: [Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.
Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.
22 Aug, 2021 | 23:51h | UTCInvited Commentary: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
Related:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter
NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval
Study from Prof Sander & co https://t.co/VAB54NokSi pic.twitter.com/wfeBsvoKhO
— The Lancet Respiratory Medicine (@LancetRespirMed) August 13, 2021
[Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.
20 Aug, 2021 | 10:03h | UTCCommentaries:
Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard
Commentary on Twitter
New large UK study confirms attrition of @Pfizer vaccine effectiveness vs Delta infections over time https://t.co/K6YRyAQq4o "By roughly 4 1/2 months after the 2nd dose, Pfizer’s shot will probably be about on par with Astra’s at preventing infections with a high viral burden" pic.twitter.com/x1Nl2BkWfn
— Eric Topol (@EricTopol) August 19, 2021
Studies: COVID vaccine protection waning against infection but not hospitalization.
19 Aug, 2021 | 09:05h | UTCStudies: COVID vaccine protection waning against infection but not hospitalization – CIDRAP
Commentary on Twitter (thread – click for more)
Very excited to share our most recent publication about #CovidVaccine effectiveness, just published today by the IVY network. Especially relevant in light of today’s news about #boosters (spoiler – I’m skeptical about the need for boosters for all). ?https://t.co/GbAxgzpo7R
— Nida Qadir, MD (@NidaQadirMD) August 18, 2021
NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.
19 Aug, 2021 | 09:06h | UTCOriginal study: Early Convalescent Plasma for High-Risk Outpatients with Covid-19 – New England Journal of Medicine
Commentary on Twitter
Convalescent plasma did not prevent disease progression in patients seen in EDs within 7 days after the onset #COVID19 symptoms. https://t.co/9gmIK3ntKH #IDTwitter pic.twitter.com/sirzn1uGL0
— NEJM (@NEJM) August 18, 2021
Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.
18 Aug, 2021 | 09:04h | UTCRelated:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter (thread – click for more)
Mix and match vaccines, AZ then mRNA (@BioNTech_Group) achieves a very strong immune response against the Delta variant.
This is the 1st report to look at mix vs Delta, specifically.https://t.co/6N46cUh8HW @TheLancet pic.twitter.com/cvlHp2XtXJ— Eric Topol (@EricTopol) August 17, 2021
FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.
16 Aug, 2021 | 01:22h | UTCCommentaries:
CDC, FDA recommend COVID booster for immune-compromised – CIDRAP
FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised – STAT
Covid booster: US approves third jab for the immunocompromised – BBC
CDC Panel Recommends 3rd Vaccine Dose For Immunocompromised People – NPR
6 Things To Know If You’re Immunocompromised And Considering A 3rd Shot – NPR
CDC recommends third Covid-19 vaccine dose for certain immunocompromised people – CNN
Commentary on Twitter
The Infectious Diseases Society of America (IDSA) supports the @FDA and @CDCgov's decision to authorize a supplemental vaccine dose for immunocompromised patients.
Read our statement: https://t.co/odzzSgIxnY pic.twitter.com/4PZfUwpjhM
— IDSA (@IDSAInfo) August 13, 2021
Study suggests a potential protective benefit from MMR and TDP vaccines in reducing the risk of severe Covid-19 infections.
16 Aug, 2021 | 01:04h | UTC
Commentary on Twitter
New @MedCellPress
Prior Measles-Mumps-Rubella (MMR) or Tetanus-Diptheria-Pertussis (Tdap) vaccination induces a T-cell response that overlaps with #SARSCoV2 and appears to offer some (~20-30%) protection from severe Covid-19https://t.co/fYT7Qole8s pic.twitter.com/hMkHXvNQYU— Eric Topol (@EricTopol) August 14, 2021
Opinion: Time for a smart approach to boosters.
13 Aug, 2021 | 09:51h | UTCTime for a Smart Approach to Boosters – Think Global Health